SDC1 and neoplasm: In studies with another OV, HSV-1 has been reported to infect myeloma cell lines and CD138+ primary cells, reduce the tumor volume after intratumoral injection [56], and exhibit enhanced antimyeloma effects in combination with lenalidomide [57].